MorphoSys AG logo

MorphoSys AG

WBO:MOR (Germany)   Ordinary Shares
€ 67.80 (+0.07%) Apr 22
At Loss
P/B:
51.96
Market Cap:
€ 2.56B ($ 2.73B)
Enterprise V:
€ 2.51B ($ 2.68B)
Volume:
-
Avg Vol (2M):
63.00
Also Trade In:

Business Description

Description
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Name Current Vs Industry Vs History
Cash-To-Debt 1.07
Equity-to-Asset 0.02
Debt-to-Equity 12.97
Debt-to-EBITDA -12.44
Altman Z-Score 0.43
Distress
Grey
Safe
Beneish M-Score -3.19
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 75.76
9-Day RSI 76.46
14-Day RSI 76.83
6-1 Month Momentum % 162.24
12-1 Month Momentum % 253.94

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.08
Quick Ratio 2.84
Cash Ratio 2.58
Days Inventory 301.86
Days Sales Outstanding 98.58
Days Payable 524.66

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.7
Shareholder Yield % 2.09

Financials (Next Earnings Date:2024-05-03 Est.)

WBO:MOR's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

MorphoSys AG Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 238.361
EPS (TTM) (€) -5.52
Beta 0.14
Volatility % 96.68
14-Day RSI 76.83
14-Day ATR (€) 0.23977
20-Day SMA (€) 67.403
12-1 Month Momentum % 253.94
52-Week Range (€) 16.165 - 68
Shares Outstanding (Mil) 37.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

MorphoSys AG Filings

Filing Date Document Date Form
No Filing Data

MorphoSys AG Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

MorphoSys AG Frequently Asked Questions

What is MorphoSys AG(WBO:MOR)'s stock price today?
The current price of WBO:MOR is €67.80. The 52 week high of WBO:MOR is €68.00 and 52 week low is €16.17.
When is next earnings date of MorphoSys AG(WBO:MOR)?
The next earnings date of MorphoSys AG(WBO:MOR) is 2024-05-03 Est..
Does MorphoSys AG(WBO:MOR) pay dividends? If so, how much?
MorphoSys AG(WBO:MOR) does not pay dividend.

Press Release

Subject Date
No Press Release